Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new treatment combo is delivering "unprecedented" survival gains for HER2-positive gastroesophageal cancer. Phase 3 trial data from HERIZON-GEA-01 showed zanidatamab-based regimens extended median overall survival by up to 8 months over the old standard, with 40% of patients alive at 3 years in the triple-drug arm — a figure experts say would have been difficult to envision just years ago.
A landmark phase 3 trial is reshaping how doctors treat HER2-positive advanced gastroesophageal adenocarcinoma. Data from the HERIZON-GEA-01 trial, presented at ESMO 2026, showed that zanidatamab-hrii (Ziihera) — a bispecific HER2-directed antibody — combined with chemotherapy, with or without the immunotherapy agent tislelizumab-jsgr (Tevimbra), significantly outperformed the longtime standard of trastuzumab plus chemotherapy. The FDA had already approved zanidatamab combinations in August based on earlier interim data.
The biggest headline? The triple-drug regimen (zanidatamab + tislelizumab + chemo) pushed the 3-year survival rate to nearly 40% — compared to just 23% with trastuzumab. Experts called this "truly remarkable" and "unprecedented" for a disease where long-term survival has historically been rare. Notably, benefits were seen regardless of PD-L1 status, a meaningful departure from pembrolizumab-based regimens.
By the Numbers:
Why it matters: This trial establishes a new first-line standard of care for HER2-positive metastatic gastroesophageal cancer — a disease with historically poor outcomes. The survival gains are substantial, though clinicians will need to proactively manage diarrhea, the most common serious side effect.
